Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 10, 2016 - Issue 1
Submit an article Journal homepage
698
Views
27
CrossRef citations to date
0
Altmetric
Review

Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?

Laura De FerrariAllergy and Respiratory Diseases, IRCCS San Martino-IST, University of Genoa, Genoa, Italy
,
Alessandra ChiapporiAllergy and Respiratory Diseases, IRCCS San Martino-IST, University of Genoa, Genoa, Italy
,
Diego BagnascoAllergy and Respiratory Diseases, IRCCS San Martino-IST, University of Genoa, Genoa, Italy
,
Anna Maria RiccioAllergy and Respiratory Diseases, IRCCS San Martino-IST, University of Genoa, Genoa, Italy
,
Giovanni PassalacquaAllergy and Respiratory Diseases, IRCCS San Martino-IST, University of Genoa, Genoa, Italy
&
Giorgio Walter CanonicaAllergy and Respiratory Diseases, IRCCS San Martino-IST, University of Genoa, Genoa, ItalyCorrespondence[email protected]
Pages 29-38 | Published online: 13 Nov 2015

References

  • Papers of special note have been highlighted as:
  • * of interest
  • ** of considerable interest
  • Global Initiative for Asthma (GINA). From the Global Strategy for Asthma Management and Prevention [Internet]. 2015 [cited 2015 Jul 10]. Available from: http://www.ginasthma.org/
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373.
  • Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126:926–938.
  • Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–304. Erratum in: N Engl J Med. 2010;363:1092.
  • Cox C, Kjarsgaard M, Surette MG, et al. A multidimensional approach to the management of severe asthma: inflammometry, molecular microbiology and bronchial thermoplasty. Can Respir J. 2015;22:221–224. pii: 16891.
  • Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012;42:650–658.
  • Gustafsson M, Nestor CE, Zhang H, et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med. 2014;6:82.
  • Drazen JM. A step toward personalized asthma treatment. N Engl J Med. 2011;365:1245–1246.
  • Braido F, Holgate S, Canonica GW. From “blockbusters” to “biosimilars”: an opportunity for patients, medical specialists and health care providers. Pulm Pharmacol Ther. 2012;25:483–486.
  • Cazzola M, Novelli G. Biomarkers in COPD. Pulm Pharmacol Ther. 2010;23:493–500.
  • Rossi R, De Palma A, Benazzi L, et al. Biomarker discovery in asthma and COPD by proteomic approaches. Proteomics Clin Appl. 2014;8:901–915.
  • Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647–654.
  • Wagener AH, De Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70:115–120.
  • Peters MC, Mekonnen ZK, Yuan S, et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133:388–394.
  • Oreo KM, Gibson PG, Simpson JL, et al. Sputum ADAM-8 expression in increased in severe asthma and COPD. Clin Experim Allergy. 2013;44:342–352.
  • Coleman JM, Naik C, Holguin F, et al. Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset. Thorax. 2012;67:1061–1066.
  • Hosoki K, Ying S, Corrigan C, et al. Analysis of a panel of 48 cytokines in BAL fluids specifically identifies IL-8 levels as the only cytokine that distinguishes controlled asthma from uncontrolled asthma, and correlates inversely with FEV1. PLoS One. 2015;10:e0126035.
  • Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–395.

**Discovery of phenotypes on the degree of Th2 inflammation.

  • Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol. 2012;25:475–484.
  • Mauri P, Riccio AM, Rossi R, et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett. 2014;162(1 Pt A):2–10.
  • Gemicioglu B, Musellim B, Dogan I, et al. Fractional exhaled nitric oxide (FeNo) in different asthma phenotypes. Allergy Rhinol. 2014;5:157–161.
  • Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of Omalizumab in allergic asthma. an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–811.

**An interesting and complete overview on known and potential biomarkers of omalizumab effects in severe asthma management.

  • Peirsman EJ, Carvelli TJ, Hage PY, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatr Pulmonol. 2014;49:624–631.
  • Yang S, Park J, Lee YK, et al. Association of longitudinal fractional exhaled nitric oxide measurements with asthma control in atopic children. Respir Med. 2015;109:572–579.
  • Di Gangi IM, Pirillo P, Carraro S, et al. Online trapping and enrichment ultra-performance liquid chromatography-tandem mass spectrometry method for sensitive measurement of “arginine-asymmetric dimethylarginine cycle” biomarkers in human exhaled breath condensate. Anal Chim Acta. 2012;754:67–74.
  • Carraro S, Giordano G, Reniero F, et al. Asthma severity in childhood and metabolomic profiling of breath condensate. Allergy. 2013;68:110–117.
  • Kazani S, Planaguma A, Ono E, et al. Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J Allergy Clin Immunol. 2013;132:547–553.
  • Schwarz K, Biller H, Windt H, et al. Characterization of exhaled particles from the human lungs in airway obstruction. J Aerosol Med Pulm Drug Deliv. 2015;28:52–58.
  • Katz LE, Gleich GJ, Hartley BF, et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc. 2014;11:531–536.
  • Cai C, Yang J, Hu S, et al. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung. 2007;185:105–112.
  • Mattarucchi E, Baraldi E, Guillou C. Metabolomics applied to urine samples in childhood asthma; differentiation between asthma phenotypes and identification of relevant metabolites. Biomed Chromatogr. 2012;26:89–94.
  • Bossley CJ, Fleming L, Gupta A, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol. 2012;129:974-82.e13.
  • Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133:1557-63.e5.
  • Simpson JL, McElduff P, Gibson PG. Assessment and reproducibility of non-eosinophilic asthma using induced sputum. Respiration. 2010;79:147–151.
  • Rossall MR, Cadden PA, Molphy SD, et al. Repeatability of induced sputum measurements in moderate to severe asthma. Respir Med. 2014;108:1566–1568.
  • Mosmann TR, Cherwinski HM, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of limphokine activities and secreted proteins. J Immunol. 1986;136:2348–2357.
  • Del Prete GF, De Carli M, Mastromauro C, et al., J Clin Invest. 1991;88:346–350.
  • Dunn RM, Wechsler ME. Anti-interleukin therapy in asthma. Clin Pharmacol Ther. 2015;97:55–65.
  • Mory Y, Iwasaki H, Kohno K, et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitors. J Exp Med. 2009;206:183–193.
  • Farahani R, Sherkat R, Hakemi MG, et al. Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Adv Biomed Res. 2014;3:127.
  • Siracusa MC, Comeau MR, Artis D. New insights into basophils biology: initiatiors, regulators, and effectors of type 2 inflammation. Ann N Y Acad Sci. 2011;1217:166–177.
  • Vatrella A, Fabozzi I, Calabrese C, et al. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014;7:123–130.
  • Dweik RA, Boggs PB, Erzurum SC, et al. An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO)for Clinical Applications. Am J Respir Crit Care Med. 2011;184:602–615.
  • Conway SJ, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014;71:1279–1288.
  • Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-derived periostin in TFG-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA. 2010;107:14170–14175.
  • Matsumoto H. Serum periostin: a novel biomarker for asthma management. Allergol Int. 2014;63:153–160.
  • Wu D, Zhou J, Bi H, et al. CCL11 as a potential diagnostic marker for asthma?. J Asthma. 2014;51:847–854.
  • Comhair SA, Erzurum SC. Redox control of asthma: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2010;12:93–124.
  • Raundhal M, Morse C, Khare A, et al. High IFN-gamma and slow SLPI mark severe asthma in mice and humans. J Clin Invest. 2015;125:3037–3050.
  • Roussel L, Houle F, Chan C, et al IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol. 2010;184:4531–4537.
  • Phenotype. Merriam-Webster’s Collegiate® English Dictionary [Internet]. 12th ed. Merriam Webster Inc.; 2008 [cited 2015 Jul 16]. Available from: http://merriam-webster.com
  • Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. The. Journal of Allergy and Clinical Immunology. 2011;127:355–360.
  • Chung KF. Defining phenotypes in asthma: a step towards personalized medecine. Drugs. 2014;74:719–728.
  • Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001–1008.

**Authors identified for the first time neutrophilic inflammation in mild asthmatics and found an association between clinical variables and different amounts of eosinophilic inflammation.

  • Gibson PG, Simpson JL, Hankin R, et al. Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma. Thorax. 2003;58:116–121.
  • Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113:101–108.

**An intresting study on phenotypic differences between early-onset severe asthma as compared with late-onset disease.

  • Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315–323. 37.
  • Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2011;127:382–389.
  • Schatz M, Hsu JW, Zeiger RS, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2014;133:1549–1556.
  • Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007;104:15858–15863.

**This study began the concept of molecular phenotyping.

**High serum periostin identified as predicting biomarkers of lebrikizumab treatment outcome.

  • Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Resp J. 2013;41:330–338.
  • Humbert M, Berger W, Rapatz G, et al. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy. 2008;63:592–596.
  • Hanania NA, Alpan O, Hamilos DL, et al Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–582.
  • Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralfa antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181:788–796.
  • Slager RE, Hawkins GA, Ampleford EJ, et al. IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. J Allergy Clin Immunol. 2010;126:875–878.
  • Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J Allergy Clin Immunol. 2012;130:516-22. e4.
  • Chu HW, Balzar S, Wesrcott JY, et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin Exp Alllergy. 2002;32:1558–1565.
  • Woolley KL, Gibson PG, Carty K, et al. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med. 1996;154:237–243.
  • Ten Brinke A, Zwinderman AH, Sterk PJ, et al. “Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med. 2004;170:601–605.
  • Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659.
  • Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–984.
  • Nair P. Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med. 2014;371:1249–1251.
  • Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Resp Crit Care Med. 2011;184:1125–1132.
  • Dahlèn SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:9–14.
  • Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370:1422–1431.
  • Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophils levels. N Engl J Med. 2013;368:2455–2466.

*Effectiveness of anti-IL4Ralpha on Th2 inflammation and pulmonary function.

  • Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol. 2010;11:577–584.
  • Black JL, Roth M. Intrinsic asthma: is it intrinsic to the smooth muscle?. Clin Exp Allergy. 2009;39:962–965.
  • Holguin F, Bleecker ER, Busse WW, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol. 2011;127:1486-93. e2.
  • Lugogo NL, Kraft M, Dixon AE. Does obesity produce a distinct asthma phenotype?. J Appl Physiol. 2010;108:729–734.
  • Calixto MC, Lintomen L, Schenka A, et al. Obesity enhances eosinophilic inflammation in a murine model of allergic asthma. Br J Pharmacol. 2010;159:617–625.
  • Holguin F, Rojas M, Brown LA, et al. Airway and plasma leptin and adiponectin in lean and obese asthmatics and controls. J Asthma. 2011;48:217–223.
  • Aydin M, Koca C, Ozol D, et al. Interaction of metabolic syndrome with asthma in post-menopausal women: role of adipokines. Inflammation. 2013;36:1232–1238.
  • Dixon AE, Pratley RE, Forgione PM, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011;128:508-515. e2.
  • Lombardi C, Gargioni S, Gardinazzi A, et al. Impact of bariatric surgery on pulmonary function and nitric oxide in asthmatic and non-asthmatic obese patients. J Asthma. 2011;48:553–557.
  • Kato T, Takeda Y, Nakata T, et al Inhibition by dexamethasone of human neutrophil apoptosis in vitro. Nat Immun. 1995;14:198–208.
  • Baines KJ, Simpson JL, Wood LG, et al. Transcriptional phenotypes of asthma defined by gene expression profiling in induced sputum sample. J Allergy Clin Immunol. 2011;127:153–160.
  • Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549–558.
  • Baines KJ, Simpson JL, Wood LG, et al. Systemic upregulation of neutrophil α-defensins and serine proteases in neutrophilic asthma. Thorax. 2011;66:942–947.
  • Doe C, Bafadhel M, Siddiqui S, et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest. 2010;138:1140–1147.
  • Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177:148–155.
  • Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42:1097–1103.
  • Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med. 2011;183:299–309.
  • Bujarski S, Parulekar AD, Sharafkhaneh A, et al. The asthma COPD overlap syndrome (ACOS). Curr Allergy Asthma Rep. 2015;15:509.
  • Elborn JS. The impact of personalised therapies on respiratory medicine. Eur Respir Rev. 2013;22:72–74.
  • Chung KF, Adcock IM. Clinical phenotypes of asthma should link up with disease mechanisms. Curr Opin Allergy Clin Immunol. 2015;15:56–62.
  • Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care2. J Allergy Clin Immunol. 2015;135:299–310.
  • Holgate ST. Stratified approaches to the treatment of asthma. Br J Clin Pharmacol. 2013;76:277–291.
  • Agustí A, Antó JM, Auffray C, et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Am J Respir Crit Care Med. 2015;191:391–401. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.